GPR142 agonist - Eli Lilly

Drug Profile

GPR142 agonist - Eli Lilly

Latest Information Update: 09 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Class Antihypercalcaemics; Benzamides; Imidazoles; Small molecules
  • Mechanism of Action G protein-coupled receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 09 Mar 2018 Eli Lilly has patents pending for GPR142 agonists in Japan, Europe, South Korea, Canada, Australia and Mexico
  • 09 Mar 2018 Eli Lilly has patent protection for GPR142 agonists in USA
  • 09 Mar 2018 Phase-I clinical trials in Type-2 diabetes mellitus in USA (unspecified route) (Eli Lilly pipeline, March 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top